Establishment of a cell line for assessing drugs as canine P-glycoprotein substrates: proof of principle (Q38721012)

5 September 2017

Establishment of a cell line for assessing drugs as canine P-glycoprotein substrates: proof of principle (English)

1 reference

5 September 2017

0 references

K L Mealey

1

1 reference

5 September 2017

S Dassanayake

series ordinal

2

1 reference

5 September 2017

N S Burke

series ordinal

3

1 reference

5 September 2017

17 January 2017

1 reference

Journal of Veterinary Pharmacology and Therapeutics

5 September 2017

1 reference

5 September 2017

40

1 reference

5 September 2017

5

1 reference

5 September 2017

545-551

1 reference

describes a project that uses

5 September 2017

MDCK-P-gp

0 references

cites work

Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cells

1 reference

P-glycoprotein ABCB1: a major player in drug handling by mammals

21 January 2018

1 reference

Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs.

21 January 2018

1 reference

Biliary excretion of technetium-99m-sestamibi in wild-type dogs and in dogs with intrinsic (ABCB1-1Delta mutation) and extrinsic (ketoconazole treated) P-glycoprotein deficiency

21 January 2018

1 reference

Diazepam as a treatment for metronidazole toxicosis in dogs: a retrospective study of 21 cases

21 January 2018

1 reference

Establishment of optimized MDCK cell lines for reliable efflux transport studies

21 January 2018

1 reference

Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues

21 January 2018

1 reference

Implications of genetic polymorphisms in drug transporters for pharmacotherapy

21 January 2018

1 reference

Induction of chemoresistance in a cultured canine cell line by retroviral transduction of the canine multidrug resistance 1 gene

21 January 2018

1 reference

P-glycoprotein mediated drug interactions in animals and humans with cancer

21 January 2018

1 reference

Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line

21 January 2018

1 reference

Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene.

21 January 2018

1 reference

P-glycoprotein contributes to the blood-brain, but not blood-cerebrospinal fluid, barrier in a spontaneous canine p-glycoprotein knockout model

21 January 2018

1 reference

ABCB1-1Delta polymorphism can predict hematologic toxicity in dogs treated with vincristine

21 January 2018

1 reference

Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage

21 January 2018

1 reference

Drug-drug interaction studies: regulatory guidance and an industry perspective

21 January 2018

1 reference

Spinosad is a potent inhibitor of canine P-glycoprotein

21 January 2018

1 reference

Inhibition of P-glycoprotein by psychotherapeutic drugs in a canine cell model

21 January 2018

1 reference

P-gp substrate-induced neurotoxicity in an Abcb1a knock-in/Abcb1b knock-out mouse model with a mutated canine ABCB1 targeted insertion

21 January 2018

1 reference

Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JVP.12390

1 reference

5 September 2017

1 reference